Meet The Team
Founder & Managing Director
​
Necdet Gunsoy, MPH PhD
​​
​
Necdet Gunsoy has over a decade of technical and leadership expertise in the pharmaceutical industry, specializing in health economics and outcomes research (HEOR), health technology assessment (HTA), indirect treatment comparisons (ITC), and real world evidence (RWE). He has a proven track record of developing reimbursement evidence and economic models for global markets, including key regions such as the UK, Germany, France, and Canada. Necdet's extensive leadership experience includes building and managing large technical teams, launch evidence strategy planning, preparation, and execution. His technical knowledge and strategic insights have made significant contributions to market access and pricing strategies in diverse therapeutic areas.
​​
Consultant, Evidence Synthesis and Health Economics
Nadine Younan, PhD​​​​
​
Nadine brings over a decade of experience in medical research, with a specialised focus on dementia. During this time, she developed strong capabilities in medical writing, publication development, and scientific communication.​
Nadine later moved into the field of health technology assessment, where she has built a robust background in evidence synthesis and economic modelling. She now brings expertise in cost-effectiveness and budget-impact modelling, systematic literature reviews, and statistical analysis using Excel, R, and STATA.​
Her strong mathematical mindset, combined with her determination, technical rigour, strategic insight, and excellent communication skills, positions her as an asset to the team.
Consultant, Statistics
Robin Philip​
​
Robin brings a background in applied statistics and computer science. He has worked as a statistician across the UK and Australia in academia, government, and CRO environments, contributing to national audits and clinical research.​
In the UK, he has over five years of experience analyzing real-world datasets, developing Shiny applications, and leading digital health studies in RWE.​
Robin’s modelling experience includes survival analysis, longitudinal methods, and machine-learning models, including building neural networks from the ground up. His programming skills span R, Python, SAS, JavaScript, and Excel.
​
.png)
Senior Analyst
Jiumei Gao
​​
​
Jiumei brings over two years of healthcare consultancy experience, specializing in market access strategies and health economics across global markets. Her fluency in both Chinese and Japanese makes her perfectly positioned to navigate APAC marketplaces. Before entering consultancy, she worked in the non-profit sector, where she was committed to enhancing patient outcomes.
​
​
​
​
​
​
​
​
Analyst
Chaitanyamayee Kalakota
​​
​
Chaitanyamayee brings a unique combination of expertise in pharmaceutical sciences and health economics. After completing her Bachelor’s in pharmaceutical science and a master's in pharmacy practice, she discovered her passion for health economics and went on to earn an MSc in Health Economics from the University of York. Her dissertation, “Producing robust estimates of cost-effectiveness in the presence of data gaps: assessment of NICE HST appraisals” explored the rare diseases where she conducted a targeted review of HST appraisals and developed an early cost-effectiveness model to address the uncertainty where data limitations are common.
​
​
Analyst
Mingshu Yan, PhD
​​​​
Mingshu completed a DPhil in Population Health at the University of Oxford, where he analysed large-scale cohort data to investigate lifestyle and cardiometabolic determinants of disease outcomes. During his doctoral research, he developed strong capabilities in systematic literature review, statistical modelling, evidence synthesis, and critical appraisal, working extensively with R and SAS.​
Prior to his doctoral studies, he held roles in national public health organisations, where he managed large international collaborations and contributed to strategic planning, programme delivery, and policy development across infectious disease and global health initiatives. These roles equipped him with robust capabilities in programme management, stakeholder engagement, and translating evidence into real-world impact.